

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC, MYLAN
PHARMACEUTICALS INC., BRECKENRIDGE PHARMACEUTICAL,
INC., and ALEMBIC PHARMACEUTICALS, LTD.,
Petitioners,

v.

RESEARCH CORPORATION TECHNOLOGIES, INC.
Patent Owner

Case IPR2016-00204¹
Patent RE38,551 E

PETITIONER'S UPDATED EXHIBIT LIST

Petitioner's Ex. No.	Exhibit Name
1001	U.S. Patent No. RE38,551
1002	Declaration of Dr. Binghe Wang
1003	Declaration of Dr. Clayton Heathcock from IPR2014-01126
1004	Joint Statement of Uncontested Facts
1005	U.S. Patent No. 5,773,475
1006	Excerpt from U.S. Patent Application No. 08/818,688
1007	District Court Claim Construction Opinion
1008	Philippe LeGall, 2-Substituted-2-acetamido-N-benzylacetamides. Synthesis, Spectroscopic and Anticonvulsant Properties (Dec. 1987)
1009	U.S. Patent No. 5,378,729
1010	Choi et al., <i>Trimethylsilyl Halides: Effective Reagents for the Synthesis of β-Halo Amino Acid Derivatives</i> , Tet. Lett., Vol. 36(39), pg. 7011 (1995)
1011	Purdie et al., <i>The Alkylation of Sugars</i> , J.A.C.S. Vol. 83, pg. 1021 (1903)
1012	Kohn et al., <i>Preparation and Anticonvulsant Activity of a Series of Functionalized α-Heteroatom-Substituted Amino Acids</i> , J. Med. Chem. Vol. 34, pg. 2444 (1991)
1013	Silverman, R. B., <i>The Organic Chemistry of Drug Design and Drug Action</i> , Academic Press (1992)
1014	Development of New Stereoisomeric Drugs, U.S. F.D.A., May 1, 1992

1015	Cortes <i>et al.</i> , <i>Effect of Structural Modification of the Hydantoin Ring on Anticonvulsant Activity</i> , J. Med. Chem., Vol. 28, pg. 601 (1985)
1016	LeGall <i>et al.</i> , <i>Synthesis of Functionalized Non-Natural Amino Acid Derivatives via Amidoalkylation Transformations</i> , Int. J. Peptide Protein Res. Vol. 32, pg. 279 (1988)
1017	Kohn <i>et al.</i> , <i>Synthesis and Anticonvulsant Activities of α-Heterocyclic α-Acetamido-N-benzylacetamide Derivatives</i> , J. Med. Chem. Vol. 36, pg. 3350 (1993)
1018	Kohn <i>et al.</i> , <i>Preparation and Anticonvulsant Activity of a Series of Functionalized α-Aromatic and α-Heteroaromatic Amino Acids</i> , J. Med. Chem. Vol. 33, pg. 919 (1990)
1019	U.S. Patent No. 5,654,301
1020	Patent Term Extension Request in U.S. Patent No. 5,654,301
1021	FDA Guideline for Industry, November 1994
1022	Schmidt, R., <i>Dose-Finding Studies in Clinical Drug Development</i> , Eur. J. Clin. Pharmacol, Vol. 34, pg. 15 (1988)
1023	Isbell, H. S., <i>The Optical Rotation of the Various Asymmetric Carbon Atoms in the Hexose and Pentose Sugars</i> , B. S. Jour. Research, Vol. 5, pg. 1041 (1929)
1024	Wilson and Gisvold's Textbook of Organic Medicinal Chemistry, Physicochemical Properties in Relation to Biologic Action, (Delgado J. N. & Remers W. A., eds. 1991)
1025	Thornber, C. W., <i>Isosterism and Molecular Modification in Drug Design</i> , Chem. Soc. Rev., Vol. 8(4) (1979)
1026	Reissue Declaration in Reissue of U.S. Patent No. 5,773,475
1027	Subpoena directed to The University of Houston
1028	Texas Public Information Act Requests and Responses

1029	Zhou <i>et al.</i> , <i>Decisions under Uncertainty: the Fuzzy Compromise Decision Support Problem</i> , Eng. Opt. Vol. 20, pg. 21 (1992)
1030	Mistree <i>et al.</i> , <i>A Decision-Based Perspective for the Design of Methods for Systems Design</i> , (1989)
1031	Mistree <i>et al.</i> , <i>A Decision-based Approach to Concurrent Design, Concurrent Engineering: Contemporary Issues and Modern Design Tools</i> , (Parsaei, H. R. & Sullivan W. G. Eds. 1993)
1032	Ingram W. T., <i>Concerning Periodic Points in Mappings of Continua</i> , J. Am. Math. Soc., Vol. 104(2) (1988)
1033	Mattson, <i>Current Challenges in the Treatment of Epilepsy</i> , Neurology, Vol. 44(suppl. 5), pg. 84 (1994)
1034	Löscher <i>et al.</i> , <i>New Avenues for Anti-Epileptic Drug Discovery and Development</i> , Nature Reviews: Drug Discovery, Vol. 12, pg. 12 (2013)
1035	Cohen authorized amendment in U.S. Patent Application No. 08/818,688
1036	Substitute Petition
1037	Marked-up Petition
1038	December 22, 2015 Email from M. Dowd to A. Reister, J. Robbins, and R. Longton.
1039	January 4, 2016 Email from M. Dowd to A. Reister, J. Robbins, and R. Longton.
1040	February 19, 2016 Email from M. Dowd to A. Reister.
1041	February 25, 2016 Letter from M. Dowd to A. Reister.
1042	February 25, 2016 Letter from M. Dowd to A. Reister.
1043	March 18, 2016 Email from M. Dowd to A. Reister.

1044	Docket for <i>UCB Inc. et al v. Accord Healthcare Inc. et al</i> , Case No. 1:13-cv-01206-LPS (Dist. Del.).
1045	Petitioner's Request for <i>Ex Parte</i> Reexam
1046	<i>Ex Parte</i> Reexamination Interview Summary
1047	Grant of Reexamination
1048	Transcript, Deposition of Dr. Carl Bazil (October 10, 2016)
1049	Transcript, Deposition of Dr. Christopher Velluro (October 14, 2016)
1050	Transcript, Deposition of Dr. William Roush (October 21, 2016)
1051	Keppra Vimpat Brivaracetam, 2012 Epilepsy Pipeline Update Conference, San Francisco, February 2012
1052	The Merck Veterinary Manual, Principles of Therapy of Neurological Disease, Seizure Control (Thomas Schubert)
1053	Charalambous M et al., <i>Antiepileptic Drugs' Tolerability and Safety-A Systematic Review and Meta-Analysis of Adverse Effects in Dogs</i> , BMC Veterinary Research, Vol. 12(79) (2016).
1054	Packer RMA, et al., <i>Clinical Risk Factors Associated with Anti-Epileptic Drug Responsiveness in Canine Epilepsy</i> , PLoS ONE, Vol. 9(8) (2014)
1055	Packer RMA, et al., <i>Assessment into the Usage of Levetiracetam in a Canine Epilepsy Clinic</i> , BMC Veterinary Research, Vol. 11(25) (2015)
1056	Bhatti S et al., <i>International Veterinary Epilepsy Task Force Consensus Proposal: Diagnostic Approach to Epilepsy in Dogs</i> , BMC Veterinary Research, Vol. 11(148) (2015)
1057	Landmark J., <i>Antiepileptic Drugs in Non-Epilepsy Disorders: Relations Between Mechanisms of Action and Clinical Efficacy</i> , CNS Drugs, Vol. 22(1) (2008)
1058	Aneja S. & Sharma S., <i>Newer Anti-epileptic Drugs</i> , J. Indian Pediatrics, Vol. 50, pg. 1033 (2013)
1059	Bazil CW, <i>New Antiepileptic Drugs</i> , Curr. Neurol. Neurosci. Rep., Vol. 1(4), pg. 369 (2001)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.